The structure that shields the virus’s RNA from the environment is called the capsid. The majority of capsid protein mutations may prevent HIV from invading cells. Once every six months, lenacapavir—the first capsid-based HIV inhibitor in history—is injected beneath the abdominal skin, creating a slow-release reservoir that gradually releases the medication into the circulation.
